Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Health
Adam Eckert

EXPLAINED: Why neurosense shares are soaring today | Vintage Vibes

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) shares are soaring Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.

PrimeC is designed to synergistically target several key mechanisms of amyotrophic lateral sclerosis (ALS). It's composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.